You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Sequential nephron blockade

Showing 1 - 25 of 3,764
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Acute Heart Failure, Acute Kidney Injury Trial in Chiang Mai (Spironolactone or hydrochlorothiazide, Placebo)

Recruiting
  • Acute Heart Failure
  • Acute Kidney Injury
  • Spironolactone or hydrochlorothiazide
  • Placebo
  • Chiang Mai, Thailand
    Chiang Mai University Hospital, Faculty of Medicine, Chiang Mai
Aug 16, 2020

Acute Heart Failure Trial in Rome (Metolazone, Loop Diuretics)

Unknown status
  • Acute Heart Failure
  • Rome, Lazio, Italy
    Policlinico Casilino
Nov 15, 2019

Acute Heart Failure Trial in Parma (Standard diuretic therapy, Early sequential nephron blockade)

Not yet recruiting
  • Acute Heart Failure
  • Standard diuretic therapy
  • Early sequential nephron blockade
  • Parma, PR, Italy
    UO Nefrologia, Azienda Ospedaliero-Universitaria di Parma
Aug 19, 2019

Advanced or Unresectable Melanoma Progressing After PD1 Blockade Trial in Norway, United States (ONCOS-102, Cyclophosphamide,

Completed
Has Results
  • Advanced or Unresectable Melanoma Progressing After PD1 Blockade
  • ONCOS-102
  • +2 more
  • Baltimore, Maryland
  • +3 more
Oct 11, 2021

Hypertension Resistant to Conventional Therapy Trial in São José do Rio Preto (Spironolactone, Furosemide,, Amiloride)

Completed
  • Hypertension Resistant to Conventional Therapy
  • São José do Rio Preto, São Paulo, Brazil
    Juan Carlos Yugar-Toledo
Apr 3, 2019

Diuretic Efficacy in Edematous States in Emergency Department

Recruiting
  • Edema
  • Characterization of parameters of medical history, examination and diagnostics.
  • Cologne, Germany
    University Hospital of Cologne
May 23, 2022

Heart Failure Trial in United Kingdom, United States (BAROSTIM NEO® System, Medical Management)

Active, not recruiting
  • Heart Failure
  • BAROSTIM NEO® System
  • Medical Management
  • Chandler, Arizona
  • +91 more
Jan 19, 2023

High Blood Pressure Trial in Canada, Germany, Netherlands (BAROSTIM NEO System, Medical Management)

Active, not recruiting
  • High Blood Pressure
  • BAROSTIM NEO System
  • Medical Management
  • Calgary, Alberta, Canada
  • +8 more
Nov 29, 2021

BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Melanoma Trial in Boston (drug, biological, other)

Terminated
  • BRAF V600E Mutation Present
  • +7 more
  • Boston, Massachusetts
  • +1 more
Mar 9, 2022

Acute Decompensated Heart Failure, Diuretics Resistance Trial in Cairo (Frusemide IV shots, Frusemide IV infusion)

Recruiting
  • Acute Decompensated Heart Failure
  • Diuretics Resistance
  • Frusemide IV shots
  • Frusemide IV infusion
  • Cairo, Egypt
    Faculty of Medicine, Cairo University Hospitals
Jan 26, 2021

Acute Kidney Injury, HIE Trial in Oklahoma City (Single Dose Theophylline, Repeat Dose Theophylline, Placebo)

Not yet recruiting
  • Acute Kidney Injury
  • HIE
  • Single Dose Theophylline
  • +2 more
  • Oklahoma City, Oklahoma
    University of Oklahoma Health Sciences Center
May 2, 2023

Bladder Tumor Trial in Gwangju (Rocuronium Bromide, Nerve stimulator)

Not yet recruiting
  • Bladder Tumor
  • Rocuronium Bromide
  • Nerve stimulator
  • Gwangju, Korea, Republic of
    Chosun University Hospital
May 22, 2023

NSCLC Trial in Nanjing (NK510, Tislelizumab,atezolizumab or sugemalimab)

Recruiting
  • NSCLC
  • NK510
  • Tislelizumab，atezolizumab or sugemalimab
  • Nanjing, Jiangsu, China
    General Hospital of Eastern Theater Command
Oct 23, 2023

Primary Aldosteronism, Endocrine Hypertension Trial (Cinnarizine, NIFEdipine ER)

Not yet recruiting
  • Primary Aldosteronism
  • Endocrine Hypertension
  • (no location specified)
Jan 12, 2023

Gastric Cancer Trial in Shanghai (NK510, Tislelizumab,atezolizumab or Trastuzumab)

Enrolling by invitation
  • Gastric Cancer
  • NK510
  • Tislelizumab，atezolizumab or Trastuzumab
  • Shanghai, China
    Shanghai Tenth People's Hospital
Oct 22, 2023

Early On-treatment Transcriptional Profiling as Predictor of

Recruiting
  • HER2-positive Breast Cancer
  • +2 more
  • Trastuzumab (neoadjuvant)
  • +2 more
  • Hospitalet de Llobregat, Barcelona, Spain
    Institut Català d'Oncologia l'Hospitalet
Jun 12, 2023

Pancreas Cancer, Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma Trial in Germany (Romidepsin, Azacitidine,

Recruiting
  • Pancreas Cancer
  • +2 more
  • Essen, Germany
  • +8 more
May 17, 2022

Breast Cancer, Estrogen Receptor Positive Tumor, HER2-positive Breast Cancer Trial in Worldwide (Paclitaxel, Trastuzumab,

Active, not recruiting
  • Breast Cancer
  • +2 more
  • Brasschaat, Belgium
  • +53 more
Nov 29, 2022

Unmethylated Glioblastoma Trial in Saint Louis (Personalized Neoantigen DNA vaccine, Retifanlimab, TDS-IM v 2.0 electroporation

Not yet recruiting
  • Unmethylated Glioblastoma
  • Personalized Neoantigen DNA vaccine
  • +2 more
  • Saint Louis, Missouri
    Washington University School of Medicine
Feb 14, 2023

Fluid Overload, Heart Failure Acute Trial in Baltimore (Metolazone 60 minutes prior to furosemide, Metolazone concurrently with

Terminated
Has Results
  • Fluid Overload
  • Heart Failure Acute
  • Metolazone 60 minutes prior to furosemide
  • Metolazone concurrently with furosemide
  • Baltimore, Maryland
    University of Maryland Medical Center
Sep 25, 2021

Analgesia, Acute Pain, Upper Extremity Injury Trial in Santiago (Bupivacaine Hydrochloride, Bupivacaine Hydrochloride with

Recruiting
  • Analgesia
  • +2 more
  • Bupivacaine Hydrochloride
  • Bupivacaine Hydrochloride with Dexamethasone
  • Santiago, Metropolitan, Chile
    Hospital Clínico Universidad de Chile
Jan 2, 2023

Cadonilimab, Clear Cell Renal Cell Carcinoma, Neoadjuvant Therapy Trial in Guangzhou (Cadonilimab Combined With Lenvatinib)

Recruiting
  • Cadonilimab
  • +2 more
  • Cadonilimab Combined With Lenvatinib
  • Guangzhou, Other (Non U.s.), China
    Sun Yat-sen University Cancer Center
Nov 16, 2023

Renal Cell Carcinoma Trial in Guangzhou (Pucotenlimab Combined With Lenvatinib)

Not yet recruiting
  • Renal Cell Carcinoma
  • Pucotenlimab Combined With Lenvatinib
  • Guangzhou, Other (Non U.s.), China
    Sun Yat-sen University Cancer Center
Nov 10, 2023

Locally Advanced or Metastatic Melanoma Trial (CBL0137, Ipilimumab, Nivolumab)

Not yet recruiting
  • Locally Advanced or Metastatic Melanoma
  • (no location specified)
Aug 10, 2022

Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer Trial in United States (GRT-C903, GRT-R904, nivolumab)

Recruiting
  • Non-Small Cell Lung Cancer
  • +4 more
  • GRT-C903
  • +3 more
  • Phoenix, Arizona
  • +13 more
Jan 30, 2023